Get started with Myriad's Prenatal Screening

Request more information about how Myriad’s prenatal screening options can benefit your patients.




Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time by using the unsubscribe link or instructions in any email communications we send. For further information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

Hidden Fields











Contact Information

Prequel®
Prenatal Screen with AMPLIFY™ Technology

Plan on getting results for 99.9% of your patients at 10 weeks, even those with high BMI

Fetal fraction plays an important role in delivering prenatal cell-free DNA (cfDNA) screening results to your patients. Low fetal fraction, which is more prevalent among patients that present with high BMI, can cause sample failure. Prequel with AMPLIFY technology enriches fetal fraction to deliver results to 99.9% of ALL patients, even those with high BMI.

Prequel®
Prenatal Screen with AMPLIFY™ Technology

Plan on getting results for 99.9% of your patients at 10 weeks, even those with high BMI

Fetal fraction plays an important role in delivering prenatal cell-free DNA (cfDNA) screening results to your patients. Low fetal fraction, which is more prevalent among patients that present with high BMI, can cause sample failure. Prequel with AMPLIFY technology enriches fetal fraction to deliver results to 99.9% of ALL patients, even those with high BMI.

Let's chat!

Schedule an appointment with your Prequel representative to learn more about:

Technology

AMPLIFY enriches fetal fraction for every single patient so you can have more confidence in the results while reducing repeat tests.

Financial assistance

Myriad Genetics provides affordable access to prenatal genetic screening through financial assistance programs for qualified patients.

Patient education

Myriad offers you and your patients on-demand access to board-certified genetic counselors for pre- and post-test education.

To schedule an appointment, please fill out the form.

About fetal fraction

Use this slider to see for yourself how Prequel with AMPLIFY technology more than doubles the fetal fraction for all patients. Notice that patients with less than 4% fetal fraction who may have experienced a sample failure, received a result with Prequel.

Image comparison - before Image comparison - after
Play button

Prequel patient story

Meet Hannah and family

Hear how non-invasive prenatal screening provided early insights into Hannah’s pregnancy and helped their family plan and prepare.

Hear Hannah’s story

Impact of low fetal fraction on high BMI patients

50%

of female patients present with high BMI1

Patients with high BMI may have lower fetal fraction in prenatal cfDNA screening2

Up to

24.3%

of cfDNA non-invasive prenatal screen failures are due to reduced fetal fraction3

Sample failures may mean:4,5

  • Increased patient anxiety
  • Decreased time to prepare in case of high-risk results
  • Increased turn-around time
  • Increased invasive diagnostic procedures

Prequel resources

See all resources

References:

  1. Deputy NP, Dub B, Sharma AJ. Prevalence and Trends in Prepregnancy Normal Weight – 48 States, New York City, and District of Columbia, 2011-2015. MMWR Morb Mortal Wkly Rep. 2018;66(51-52):1402-1407. Published 2018 Jan 5. doi:10.15585/mmwr.mm665152a3.
  2. Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenat Diagn. 2020;40(3):333-341. doi:10.1002/pd.5603.
  3. Yared E, et al. Obesity increases the risk of failure of noninvasive prenatal screening regardless of gestational age. Am J Obstet Gynecol. 2016 Sep;215(3):370.e1-370.e6.
  4. Artieri CG, Haverty C, Evans EA, et al. Noninvasive prenatal screening at low fetal fraction: comparing whole-genome sequencing and single-nucleotide polymorphism methods. Prenat Diagn. 2017;37(5):482-490. doi:10.1002/pd.5036.
  5. Van Schendel RV, et al. Women’s Experience with Non-Invasive Prenatal Testing and Emotional Well-being and Satisfaction after Test-Results. J Genet Couns. 2017 Dec;26(6):1348-1356. doi: 10.1007/s10897-017-0118-3. Epub 2017 Jun 30.PMID: 28667567.
Get started Get Started

Locations

United States
Europe
Japan